Tags

Type your tag names separated by a space and hit enter

A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.
Child Psychiatry Hum Dev. 2014; 45(2):185-92.CP

Abstract

Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents. This is the first prospective randomized clinical trial comparing the safety and efficacy of these two medications in patients with autism spectrum disorders. Fifty nine children and adolescents with autism spectrum disorders were randomized to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was change in Aberrant Behavior Checklist (ABC) scores. Adverse events were assessed. Aripiprazole as well as risperidone lowered ABC scores during 2 months. The rates of adverse effects were not significantly different between the two groups. The safety and efficacy of aripiprazole (mean dose 5.5 mg/day) and risperidone (mean dose 1.12 mg/day) were comparable. The choice between these two medications should be on the basis of clinical equipoise considering the patient's preference and clinical profile.

Authors+Show Affiliations

School of Medicine, Research Center for Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences, School of Medicine, Shiraz, Iran, ghanizadeha@hotmail.com.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23801256

Citation

Ghanizadeh, Ahmad, et al. "A Head-to-head Comparison of Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a Randomized Double Blind Clinical Trial." Child Psychiatry and Human Development, vol. 45, no. 2, 2014, pp. 185-92.
Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45(2):185-92.
Ghanizadeh, A., Sahraeizadeh, A., & Berk, M. (2014). A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development, 45(2), 185-92. https://doi.org/10.1007/s10578-013-0390-x
Ghanizadeh A, Sahraeizadeh A, Berk M. A Head-to-head Comparison of Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a Randomized Double Blind Clinical Trial. Child Psychiatry Hum Dev. 2014;45(2):185-92. PubMed PMID: 23801256.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. AU - Ghanizadeh,Ahmad, AU - Sahraeizadeh,Aliakbar, AU - Berk,Michael, PY - 2013/6/27/entrez PY - 2013/6/27/pubmed PY - 2015/4/17/medline SP - 185 EP - 92 JF - Child psychiatry and human development JO - Child Psychiatry Hum Dev VL - 45 IS - 2 N2 - Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents. This is the first prospective randomized clinical trial comparing the safety and efficacy of these two medications in patients with autism spectrum disorders. Fifty nine children and adolescents with autism spectrum disorders were randomized to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was change in Aberrant Behavior Checklist (ABC) scores. Adverse events were assessed. Aripiprazole as well as risperidone lowered ABC scores during 2 months. The rates of adverse effects were not significantly different between the two groups. The safety and efficacy of aripiprazole (mean dose 5.5 mg/day) and risperidone (mean dose 1.12 mg/day) were comparable. The choice between these two medications should be on the basis of clinical equipoise considering the patient's preference and clinical profile. SN - 1573-3327 UR - https://www.unboundmedicine.com/medline/citation/23801256/A_head_to_head_comparison_of_aripiprazole_and_risperidone_for_safety_and_treating_autistic_disorders_a_randomized_double_blind_clinical_trial_ L2 - https://doi.org/10.1007/s10578-013-0390-x DB - PRIME DP - Unbound Medicine ER -